Skip to main content
PLOS One logoLink to PLOS One
. 2023 Sep 1;18(9):e0283295. doi: 10.1371/journal.pone.0283295

Antimicrobial effect of oral care gel containing hinokitiol and 4-isopropyl-3-methylphenol against intraoral pathogenic microorganisms

Hiroshi Ohara 1,2,*, Keita Odanaka 1, Miku Shiine 1, Masataka Hayasaka 1
Editor: José António Baptista Machado Soares3
PMCID: PMC10473516  PMID: 37656688

Abstract

Objective

Deterioration of oral hygiene is closely related to an increase in severity and mortality of corona virus disease-19 (COVID-19), and also contributes to the development of various diseases such as aspiration pneumonia or Alzheimer’s. Oral care is attracting high interest in Japan, which has entered a super-aging society. In this study, we aimed to investigate whether commercially available Hinora® (HO), an oral care gel containing hinokitiol and 4-isopropyl-3-methylphenol (IPMP), has biofilm formation inhibitory and antimicrobial activities against various intraoral pathogen microorganisms.

Method

Candida species, Aggregatibacter actinomycetemcomitans, Staphylococcus aureus, and Pseudomonas aeruginosa were selected during the study period, all of which were analyzed using antimicrobial disc, microorganism turbidity, and crystal violet assays. In addition, the germ tube test using Candida albicans (C. albicans) was performed with a modification of Mackenzie’s method. Images for morphological observation of the germ tubes were acquired using an inverted microscope. For comparison between products, we used Refrecare® (RC), which only contains hinokitiol (not containing IPMP).

Results

All the intraoral pathogenic microorganisms showed drug susceptibility against undiluted forms of HO and/or RC. In particular, HO was more effective at lower concentrations than RC. In the HO-added group, inhibition circles were observed in all bacteria except P. aeruginosa when added at a concentration of 0.5 g/mL or more. The optical density values at 590 nm (crystal violet) and/or 600 nm (microorganism turbidity) of all the fungi and bacteria were significantly lower when cultured in medium with HO. Inhibition of growth or biofilm formation was observed when HO was added at a concentration of 0.05 g/mL or higher. To investigate the action mechanism of HO, germ tube tests were performed in C. albicans. The results showed that culturing C. albicans in soybean-casein digest broth with HO (0.05 g/mL) significantly suppressed germ tube formation.

Conclusions

These data suggest that oral care gel-containing hinokitiol and IPMP has strong biofilm formation inhibitory activity, as well as antifungal and antimicrobial effects against Candida fungi and multiple intraoral pathogenic microorganisms. Therefore, it may be a promising treatment option for oral infections.

Introduction

Oral infections such as oral candidiasis and periodontal disease are a series of polymicrobial conditions that affect the oral mucosa and tooth root [1]. Deterioration of oral hygiene leads to intraoral colonization by fungi or bacteria, and has been reported to contribute to systemic diseases such as gingivitis, aspiration pneumonia, deep mycosis, or increased severity and mortality in corona virus disease-19 (COVID-19) [24]. It is suggested that aspiration pneumonia, which is often seen in the elderly, is caused by oral bacteria growing in the oral cavity. In addition to periodontal pathogens, opportunistic infectious pathogenic microorganisms such as Candida, Pseudomonas, or Staphylococcus are known to easily form multi-species biofilm coaggregations intraorally, causing various systemic conditions such as those associated with diabetes mellitus, cardiovascular diseases, pulmonary diseases, and preterm birth [3, 5, 6]. The elderly population has an increased incidence of aspiration pneumonia and fever due to aspiration of oral bacteria along with decreased immune function and swallowing reflex. In particular, elderly people who require nursing care are likely to have deteriorated oral hygiene conditions due to a decrease in independence and salivary secretion, thus having an increased risk of developing pneumonia. Therefore, maintaining oral hygiene through daily oral care is important in preventing aspiration pneumonia and oral infections. Oral care is attracting high interest in Japan, a country that has entered a super-aging society. Candida species are facultative anaerobes and can grow in an environment where oxygen is sufficiently supplied, such as the oral surface and tooth surface, and in an environment where oxygen concentration is low, such as between teeth and periodontal pockets. Candida albicans (C. albicans), C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis have been isolated from the oral cavity. C. albicans is the most isolated species, but in recent years, there have been reports of infection by non-albicans Candida species [7, 8]. Proliferation of these fungi in the oral cavity can lead to superficial gingival inflammation, periodontitis, and deep-seated invasive gingival inflammation. [9]. Oral infection caused by Candida species is more likely to develop from immunodeficiency or decreased immunity owing to diabetes or human immunodeficiency virus infection [1012]. In addition, unsanitary oral conditions have been reported to contribute to the development of Alzheimer’s disease and/or increased severity and mortality in COVID-19 [1318]. Hence, periodic oral examinations and maintenance of oral hygiene are important.

To prevent the exacerbation of poor oral hygiene, it is important to keep the oral cavity clean by brushing. In treating oral infections, cleansing the oral cavity through oral care using antiseptics, as well as treatment with antifungal drugs such as amphotericin B and miconazole is very important. However, Candida species are known to easily form biofilms on the surfaces of teeth and dentures, thereby reducing the effectiveness of brushing and antifungal agents [1921]. The constituents of biofilms are polysaccharides and dead and live fungi [22]. Given that biofilms have high adhesion to the tooth surface, it is difficult to remove them all by the self-cleaning action of saliva or brushing [23]. In addition, given that biofilms form a membranous structure, drugs found in mouthwashes do not penetrate the biofilm, reducing the effectiveness of the formulation [24, 25]. Therefore, suppressing the formation of biofilms on the surfaces of teeth and dentures is very important for the prevention and treatment of oral infectious diseases. Although antimicrobial agents such as chlorhexidine gluconate and/or cetylpyridinium chloride are used as additives in commercially available oral hygiene care products such as mouthwash and toothpaste, some of them are associated with side effects and cytotoxic [26, 27]. Plant derived-products have been used as oral care reagents that have fewer adverse effects [28]. Essential oil from Matricaria chamomilla has antimicrobial effects and mouthwash containing this oil suppressed oropharynx colonization by Staphylococcus aureus (S. aureus) and Streptococcus pneumoniae in patients in the intensive care unit [29], and cinnamon and sweet basil essential oils enhanced inhibition of biofilm formation by Streptococcus mutans and Lactobacillus casei [30].

Beta-thujaplicin (hinokitiol) is a bioactive compound of an aromatic seven-member tropolone purified from Cupressaceae plants such as Chamaecyparis obtusa and Thujopsis dolabrata [31, 32]. Hinokitiol has antimicrobial effects and has been used in many daily necessities, foods, and cosmetics owing to its low toxicity to humans [3337]. However, the biological activity of this compound is not yet fully understood and there are few reports on its antimicrobial properties against opportunistic bacteria such as S. aureus or Pseudomonas aeruginosa (P. aeruginosa), which are rarely detected in oral cavities of healthy subjects but frequently detected in those of the elderly. In this study, we aimed to investigate whether oral care gels containing hinokitiol and 4-isopropyl-3-methylphenol (IPMP) (Hinora®: HO) or hinokitiol (Refrecare®: RC) have biofilm formation inhibitory and antimicrobial activities against fungi and bacteria that cause oral disease.

Material and methods

Strains and culture conditions

C. albicans (ATCC10231), C. glabrata (NBRC0622), C. krusei (NBRC1395), C. parapsilosis (NBRC1396), C. tropicalis (NBRC1400), Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) (ATCC29522), P. aeruginosa (ATCC9027), and S. aureus (ATCC6538) were purchased from the American Type Culture Collection (ATCC, Virginia, USA) or Biological Resource Center, National Institute of Technology and Evaluation (NBRC, Chiba, Japan). All fungi and bacteria, except for A. actinomycetemcomitans, were cultured under aerobic conditions, and A. actinomycetemcomitans was cultured under anaerobic conditions (5% CO2, 0% O2), using Anaero Pouch Kenki (Mitsubishi Gas Chemicals Co., Ltd., Tokyo, Japan).

In the culture using soybean-casein digest (SCD) agar medium (Nissui pharmaceutical Co., Ltd., Tokyo, Japan), each fungus and bacteria were cultured at 37°C for 24–48 h. For the culture using SCD broth (Merck KGaA, Darmstadt, Germany) with and without HO (EN Otsuka Pharmaceutical Co., Ltd., Iwate, Japan) and/or RC (EN Otsuka Pharmaceutical Co., Ltd., Iwate, Japan) (HO concentration: 0.05 g/mL, 0.1 g/mL; RC concentration: 0.05 g/mL, 0.1 g/mL), the obtained fungal and bacterial suspensions were dispensed onto 96-well polystyrene plates at a density of 200 μL/well and cultured at 37°C for 24–48 h. For all experiments, each fungus was adjusted to an optical density (OD) of 0.1–0.4 at 600 nm (equivalent to 1 × 106 colony-forming units (CFU) /mL) and inoculated at 1 × 106 CFU/mL, and each bacterium was adjusted to an OD of 0.1–0.3 at 600 nm (equivalent to 1 × 108 CFU/mL) and inoculated at 1 × 108 CFU/mL.

Antimicrobial disc diffusion assay

Each fungus and bacteria were inoculated into saline solutions to achieve a concentration of 1 × 106 or 1 × 108 CFU/mL and spread evenly on SCD agar medium. A sterilized paper disc with a diameter of 8 mm (ADVANTEC Toyo, Co., Ltd., Tokyo, Japan) coated with oral care gel-containing medium was placed on the SCD agar medium, and the fungus or bacterium was cultured at 37°C for 24 h.

Paper discs were coated with 80 μL of SCD broth and SCD broth containing HO (0.1, 0.5, and 5.0 g/mL and undiluted form) or RC (0.1, 0.5, and 5.0 g/mL and undiluted form). A paper disc coated with oral care gel-containing medium was used after 2–3 h of air drying on a clean workstation.

Microorganism turbidity and crystal violet assays

As described above, each fungus and bacteria were cultured at 37°C for 24–48 h in SCD broth and SCD broth containing HO (0.05 g/mL, 0.1 g/mL) or RC (0.05 g/mL, 0.1 g/mL). Fungal or bacterial growth was determined to be proportional to the measured OD at 600 nm by spectrophotometry. First, the absorbance of cultures was measured at 600 nm using a SpectraMax190 microplate reader (Molecular Devices Co., Ltd., Tokyo, Japan) to monitor the turbidity (i.e., possibility of proliferation of each fungus and bacterium).

Next, the medium was removed, and each well was washed twice with saline. A crystal violet aqueous solution (0.1% w/v) was added to each well (200 μL/well), and the mixture was allowed to stand at room temperature (~ 25°C) for 30 min for staining. Crystal violet is a basic purple dye having a triphenylmethane skeleton, and has been widely used for the purpose of staining the cell wall or biofilm of fungi and bacteria. It is suitable for biofilm staining at OD 590 nm [38]. Generally, biofilms are formed 24–48 h after culturing the fungus or bacterium. Herein, after staining, the crystal violet aqueous solution was removed, and each well was washed twice with saline. Ethanol was added to the well (200 μL/well), and the mixture was allowed to stand at approximately 25°C for 15 min. Then, the crystal violet stain solution was extracted from each fungus or bacterium with ethanol, and the OD was measured at 590 nm using a microplate reader to detect the biofilm in the 96-well plate.

Germ tube test

The germ tube test was performed using a modification of Mackenzie’s method [39]. C. albicans was inoculated into SCD broth or SCD broth with HO (0.05 g/mL) to a concentration of 1 × 106 CFU/mL. The fungal suspension was applied in a 6-cm dish (3 mL/dish) and cultured at 37°C for 3 h. Images for morphological observation of the germ tubes were acquired with an Olympus CKX41 camera (Olympus Co., Ltd., Tokyo, Japan). The number of germ tube-forming cells per 500 cells were divided into three sections and counted (1,500 cells in total), and compared between the control group and the HO-added group.

Statistical analysis

The statistical significance of the differences in the ratio of biofilm formation between non-treated, and HO- and RC-treated fungal or bacterial pathogens was examined using Student t test or Dunnett’s test. The statistical significance level was considered to be statistically significant when P < 0.05.

Results

The inhibitory zone formed by the undiluted solution of HO and RC for each Candida fungus was larger than that of the control group (Fig 1). The inhibition zone was larger for HO than for RC, with diameters of 24 mm (HO), 19 mm (RC) for C. albicans (Fig 1A), 25 mm (HO), 15 mm (RC) for C. glabrata (Fig 1B), 25 mm (HO), 10 mm (RC) for C. krusei (Fig 1C), 24 mm (HO), 17 mm (RC) for C. parapsilosis (Fig 1D), and 23 mm (HO), 14 mm (RC) for C. tropicalis (Fig 1E). In addition, other oral infection-causing microorganisms used in the experiments formed inhibitory zones, with diameters of 25 mm (HO), 13 mm (RC) for A. actinomycetemcomitan, 31 mm (HO), 20.5 mm (RC) for S. aureus, and 10 mm (HO), 15 mm (RC) for P. aeruginosa (Table 1). The maximum zone of inhibition was 31 mm of S. aureus in the HO-added group. In the HO-added group, inhibition circles were observed for all fungi and bacteria except P. aeruginosa at a concentration of 0.5 g/mL or higher. In the RC-added group, inhibition circles were observed for all fungi and bacteria except C. krusei at a concentration of 5.0 g/mL or higher (Table 1).

Fig 1.

Fig 1

Table 1. Inhibition zone diameter measurement (mm) in Candida spp., Aggregatibacter actinomycetemcomitans, Staphylococcus aureus, and Pseudomonas aeruginosa by Hinora® (HO) and Refrecare® (RC).

Oral care gel containing hinokitiol (g/mL) Inhibition zone diameter (mm), including a sterilized paper disc with a diameter of 8 mm (n = 1)
C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis A. actinomy S. aureus P. aeruginosa
Hinora® 0 ND ND ND ND ND ND ND ND
0.1 ND ND ND ND ND ND 12 ND
0.5 13 14 13 12 11 15 22.5 ND
5.0 18 22 15 22 16 19 26.5 ND
undiluted form 24 25 25 24 23 25 31 10
Refrecare® 0 ND ND ND ND ND ND ND ND
0.1 ND ND ND ND ND ND 9.5 ND
0.5 ND ND ND ND ND ND 16 ND
5.0 10 10 ND 10 12 9.5 20 11
undiluted form 19 15 10 17 14 13 20.5 15

ND: not detectable

Next, Candida species and bacteria were cultured in SCD broth containing HO or RC (final 0.05, 0.1 g/mL) for 24–48 h, and each fungal or bacterial growth was measured using spectrophotometry by absorbance at 600 nm OD. The OD at 600 nm was significantly lower when cultured in SCD broth containing HO or RC than that observed for the control (Fig 2). These growth suppression effects were observed when the concentration of HO or RC was 0.05 g/mL or higher.

Fig 2.

Fig 2

Subsequently, we investigated whether these oral care gels had biofilm formation inhibitory activity against each fungus and bacteria using crystal violet assays. As described above, each fungus and bacteria were cultured, and each fungal and bacterial biofilm formation was measured using spectrophotometry by absorbance at 590 nm OD. The OD at 590 nm was significantly lower when cultured in SCD broth containing HO or RC than that observed for the control (Fig 3). The addition of HO inhibited biofilm formation of all the oral infection-causing microorganisms used. The inhibitory effect of HO was observed at 0.05 g/mL or higher. RC also showed significant biofilm formation inhibitory effect against Candida species, periodontal disease bacteria, and opportunistic infectious bacteria at above 0.05 g/mL, but the effect tended to be weaker than that of HO. In contrast, HO and RC were equally effective in inhibiting biofilm formation against P. aeruginosa.

Fig 3.

Fig 3

Finally, we conducted a germ tube test of C. albicans using HO-containing SCD broth to investigate the mechanism of action of HO, which had an excellent ability to inhibit biofilm formation. The addition of HO significantly suppressed the formation of germ tubes in C. albicans (Fig 4A). Germ tube formation was inhibited even at a concentration as low as 0.05 g/mL HO, and the total number of germ tube-forming cells in 1,500 cells was significantly reduced in the HO-added group (1.7 ± 1.7/500 cells) compared to the control group (198 ± 17.1/500 cells) (P < 0.01) (Fig 4B).

Fig 4.

Fig 4

Discussion

Oral care is important not only for disease prevention or functional maintenance of teeth and surrounding tissues, but also for prevention of systemic diseases and maintenance of quality of life. In Japan, which is currently a super-aging society, in addition to oral care aimed at preventing caries and periodontal disease, the need for oral care for the elderly and those requiring nursing care is increasing [40]. Although there have been previous reports on the antimicrobial properties of hinokitiol, there are few reports that have extensively verified its antimicrobial effects against various microbes closely related to oral infections. Investigation of the antimicrobial properties of oral care products containing hinokitiol revealed the presence of antimicrobial activity against C. albicans (ATCC10231), C. glabrata (NBRC0622), C. krusei (NBRC1395), C. parapsilosis (NBRC1396), and C. tropicalis (NBRC1400), which are the main cause of oral candidiasis, at low concentration (0.05 g/mL). Furthermore, similar effects were obtained against P. aeruginosa, S. aureus, and periodontal disease bacteria (Table 1). Fig 1 shows the growth inhibition zones of Candida species. For all fungi and bacteria that cause oral infectious diseases, growth-inhibiting circles were formed around the disc containing HO or RC (Table 1). In the HO-added group, inhibition circles were observed in all bacteria except P. aeruginosa when added at a concentration of 0.5 g/mL or more. In the RC-added group, inhibition circles were observed in all bacteria except C. krusei when added at a concentration of 5.0 g/mL or more (Table 1). In addition, various fungi and bacteria described above were cultured in SCD broth with and/or without HO or RC for 24 h, and the OD of the culture was measured at 600 nm on a microplate reader to detect the turbidity (indicative of the level of proliferation of each fungus and bacteria). Growth inhibition was observed when HO or RC was added at a concentration of above 0.05 g/mL (Fig 2). The OD values at 600 nm of all the cultures were significantly reduced when cultured in media containing HO or RC. These results indicate that HO and RC have growth inhibitory effects on Candida species, as well as opportunistic and periodontal disease bacteria, and support the efficacy of hinokitiol in the dental field. The results of the disc diffusion assay and culture in SCD liquid medium showed that HO had higher antimicrobial activity than RC. Hinokitiol content is twice as much in HO when compared to that in RC (HO: 0.1%; RC: 0.05%). Moreover, 0.02% 4-isopropyl-3-methylphenol (IPMP) is present in HO but not in RC. IPMP is a typical preservative and bactericidal constituent in cosmetics and is used in commercial oral care products [41]. Phenolic compounds such as IPMP, phenoxyethanol, and ortho-phenylphenol are often thought to exhibit antimicrobial activity by damaging cell membranes and changing the membrane structure and function [42]. These facts are consistent with the observation that HO had higher antimicrobial activity than RC.

Biofilms provide optimal protection for embedded cells from antibiotics, antifungals, and the immune system, which is the main reason why biofilm-related infections are difficult to treat. In addition, microorganisms on the surface of biofilms can spread to the infectious region as they move and multiply in search of other habitats as needed [22, 43, 44]. We investigated whether oral care gels, HO and RC, could inhibit biofilm formation caused by oral infection-causing microorganisms. The addition of HO or RC at concentrations above 0.05 g/mL inhibited biofilm formation of Candida species and all oral infection-causing organisms studied (Fig 3). Biofilm formation inhibitory effects of intraoral microorganisms were stronger for HO than RC. Hence, daily use of oral care products containing hinokitiol and IPMP is thought to contribute to reducing the risk of intraoral infections.

In elderly people who require nursing care, more opportunistic bacteria such as Candida species, P. aeruginosa, S. aureus, and periodontal disease bacteria are detected in the oral cavity due to the wearing of dentures and the deterioration of biological defenses [3, 6]. In addition, a decrease in self-cleaning action due to a decrease in salivary secretion also leads to deterioration of oral hygiene. In particular, the proliferation of Candida species is closely related to the risk of death from respiratory diseases and the development of aspiration pneumonia.

Germ tube formation is one of the processes involved in adhesion, which is the first step in the biofilm formation of Candida species [23, 45]. Therefore, inhibition of germ tube expression contributes to the control of Candida species infection. The formation of germ tubes is known to be promoted by stimulation with proteins in serum at 37°C and is easily formed even in SCD broth [39, 46]. In this study, to investigate the mechanism of action of HO, C. albicans was cultured in HO-containing SCD broth for 3 h, and its effect on germ tube formation was investigated. The results showed that culturing C. albicans in SCD broth with HO (0.05 g/mL) significantly suppressed germ tube formation (Fig 4). Therefore, oral care products containing hinokitiol can be expected to suppress biofilm formation of Candida species by inhibiting the germ tube formation. Hinokitiol-containing oral care gel exerts a strong biofilm formation inhibitory effect and antifungal activity against Candida species, albeit at a low concentration (0.05 g/mL) (Figs 3 and 4). Furthermore, this study revealed that hinokitiol also exhibits antimicrobial activity against P. aeruginosa, S. aureus, and periodontal disease bacteria, findings which have not been reported to date. These data suggest that the use of oral care products containing hinokitiol in oral care for the elderly requiring nursing care may prevent oral infections and contribute to the improvement of their quality of life.

It is speculated that hinokitiol inhibits biofilm formation by suppressing the expression of genes and proteins related to hyphal formation and adhesion to biogenic organisms. Kim et al. reported that hinokitiol suppresses the expression of genes involved in the adhesion process and hyphal formation and/or maintenance of C. albicans, resulting in the inhibition of biofilm formation [47]. However, whether a similar biofilm inhibition mechanism applies in non-albicans Candida species such as S. aureus and P. aeruginosa has not been demonstrated. In the future, in addition to gene expression analysis related to biofilms, morphological imaging measurements using field emission scanning electron microscopy or high-resolution transmission electron microscopy will be necessary for further elucidation of the anti-biofilm mechanism of hinokitiol, and investigation is required to evaluate the antimicrobial activity of hinokitiol in vivo.

Conclusion

In conclusion, oral care gel products containing hinokitiol were found to have biofilm formation inhibitory and antimicrobial activities against various intraoral pathogenic microorganisms. In particular, the oral care gel containing hinokitiol and IPMP strongly inhibited biofilm formation and had antimicrobial effects against multiple oral infection-causing microorganisms. These results suggest that oral care gel products containing hinokitiol are very effective in the prevention and treatment of oral infections such as oral candidiasis or periodontal disease. In addition, oral care gel products containing hinokitiol and IPMP may be particularly useful for assisting with the prevention and treatment of multiple oral infectious microorganisms.

Acknowledgments

We are also grateful to Kenichi Ogasawara and Ryosuke Kawawaki of EN Otsuka Pharmaceutical Co., Ltd. for their advice in promoting this research.

Data Availability

All relevant data are within the paper.

Funding Statement

Initials of the authors who received each award: Not applicable Grant numbers awarded to each author: There is no grant number assigned to each author. The full name of each funder: Kenichi Ogasawara and Ryosuke Kawawaki URL of each funder website: https://www.enotsuka.co.jp/ Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Touger-Decker R, Mobley CC; American Dietetic Association. Position of the American Dietetic Association: oral health and nutrition. J Am Diet Assoc. 2003;103(5):615–625. doi: 10.1053/jada.2003.50130 . [DOI] [PubMed] [Google Scholar]
  • 2.Kouanda B, Sattar Z, Geraghty P. Periodontal Diseases: Major Exacerbators of Pulmonary Diseases? Pulm Med. 2021;4712406. doi: 10.1155/2021/4712406 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fujinami W, Nishikawa K, Ozawa S, Hasegawa Y, Takebe J. Correlation between the relative abundance of oral bacteria and Candida albicans in denture and dental plaques. J Oral Biosci. 2021;63(2):175–183. doi: 10.1016/j.job.2021.02.003 . [DOI] [PubMed] [Google Scholar]
  • 4.Rajendra Santosh AB, Muddana K, Bakki SR. Fungal Infections of Oral Cavity: diagnosis, management, and association with COVID-19. SN Compr Clin Med. 2021;3(6):1373–1384. doi: 10.1007/s42399-021-00873-9 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Schlecht LM, Peters BM, Krom BP, Freiberg JA, Hänsch GM, Filler SG, et al. Systemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue. Microbiology. 2015;161(Pt 1):168–181. doi: 10.1099/mic.0.083485-0 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Muhammad AN. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim). 2017; 11(2):72–80. PubMed . [PMC free article] [PubMed] [Google Scholar]
  • 7.Muadcheingka T, Tantivitayakul P. Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. Arch Oral Biol. 2015;60(6):894–901. doi: 10.1016/j.archoralbio.2015.03.002 . [DOI] [PubMed] [Google Scholar]
  • 8.Bassetti M, Merelli M, Ansaldi F, Florentiis D, Sartor A, Scarparo C, et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS One. 2015;10(5):e0127534. doi: 10.1371/journal.pone.0127534 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: A disease of opportunity. J Fungi. 2020;6(1):15–42. doi: 10.3390/jof6010015 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Slots J, Kamma JJ. General health risk of periodontal disease. Int Dent J. 2001;51(6):417–427. doi: 10.1002/j.1875-595x.2001.tb00854.x . [DOI] [PubMed] [Google Scholar]
  • 11.Mubarak AS, Robert AA, Baskaradoss JK, Al-Zoman K, Sohail AA, Alsuwyed A, et al. The prevalence of oral Candida infections in periodontitis patients with type 2 diabetes mellitus. J Infect Public Health. 2013;6(4):296–301. doi: 10.1016/j.jiph.2012.12.007 . [DOI] [PubMed] [Google Scholar]
  • 12.Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, et al. Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000–2010. J Infect Dis. 2016;214(6):862–872. doi: 10.1093/infdis/jiw085 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kamer AR, Craig RG, Pirraglia E, Dasanayake AP, Norman RG, Boylan RJ, et al. TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. J Neuroimmunol, 2009;216(1–2):92–97. doi: 10.1016/j.jneuroim.2009.08.013 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Collcutt A, et al. Cathepsin B plays a critical role in inducing Alzheimer’s disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in mice. Brain Behav Immun. 2017;65:350–361. doi: 10.1016/j.bbi.2017.06.002 . [DOI] [PubMed] [Google Scholar]
  • 15.Larvin H, Wilmott S, Wu J, Kang J. The impact of periodontal disease on hospital admission and mortality during COVID-19 pandemic. Front Med (Lausanne). 2020;7:604980. doi: 10.3389/fmed.2020.604980 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Patel J, Sampson V. The role of oral bacteria in COVID-19. Lancet Microbe. 2020;1(3):e105. doi: 10.1016/S2666-5247(20)30057-4 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Patel J, Woolley J. Necrotizing periodontal disease: Oral manifestation of COVID-19. Oral Dis. 2021;Suppl 3(Suppl 3):768–769. doi: 10.1111/odi.13462 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Larvin H, Wilmott S, Kang J, Aggarwal VR, Pavitt S, Wu J. Additive effect of periodontal disease and obesity on COVID-19 outcomes. J Dent Res. 2021;100(11):1228–1235. doi: 10.1177/00220345211029638 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sardi JC, Almeida AM, Mendes Giannini MJM. New antimicrobial therapies used against fungi present in subgingival sites—A brief review. Arch Oral Biol. 2011;56(10):951–959. doi: 10.1016/j.archoralbio.2011.03.007 . [DOI] [PubMed] [Google Scholar]
  • 20.Colombo APV, Magalhães CB, Hartenbach FA, do Souto RM, da Silva-Boghossian CM. Periodontal-disease-associated biofilm: A reservoir for pathogens of medical importance. Microb Pathog. 2016;94:27–34. doi: 10.1016/j.micpath.2015.09.009 . [DOI] [PubMed] [Google Scholar]
  • 21.Zijnge V, van Leeuwen MBM, Degener JE, Abbas F, Thurnheer T, Gmür R, et al. Oral biofilm architecture on natural teeth. PLoS One. 2010;5(2):e9321. doi: 10.1371/journal.pone.0009321 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108. doi: 10.1038/nrmicro821 . [DOI] [PubMed] [Google Scholar]
  • 23.Nikawa H, Mikihira S, Egusa H, Fukushima H, Kawabata R, Hamada T, et al. Candida adherence and biofilm formation on oral surfaces. Nihon Shinkin Gakkai Zasshi. 2005;46(4):233–242. doi: 10.3314/jjmm.46.233 . [DOI] [PubMed] [Google Scholar]
  • 24.Zarnowski R, Sanchez H, Covelli AS, Dominguez E, Jaromin A, Bernhardt J, et al. Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis. PLoS Biol. 2018;16(10):e2006872. doi: 10.1371/journal.pbio.2006872 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Taff HT, Mitchell KF, Edward JA, Andes DR. Mechanisms of Candida biofilm drug resistance. Future Microbiol. 2013;8(10):1325–1337. doi: 10.2217/fmb.13.101 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hidalgo E, Dominguez C. Mechanisms underlying chlorhexidine-induced cytotoxicity. Toxicol In Vitro. 2001;15(4–5):271–276. doi: 10.1016/s0887-2333(01)00020-0 . [DOI] [PubMed] [Google Scholar]
  • 27.Imai H, Kita F, Ikesugi S, Abe M, Sogabe S, Nishimura-Danjobara Y, et al. Cetylpyridinium chloride at sublethal levels increases the susceptibility of rat thymic lymphocytes to oxidative stress. Chemosphere. 2017;170:118–123. doi: 10.1016/j.chemosphere.2016.12.023 . [DOI] [PubMed] [Google Scholar]
  • 28.Chandra Shekar BR, Nagarajappa R, Suma S, Thakur R. Herbal extracts in oral health care—A review of the current scenario and its future needs. Pharmacogn Rev. 2015;9(18):87–92. doi: 10.4103/0973-7847.162101 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Darvishi Khezri H, Haidari Gorji MA, Morad A, Gorji H. Comparison of the antibacterial effects of matrica & Persica™ and chlorhexidine gluconate mouthwashes in mechanically ventilated ICU patients: a double blind randomized clinical trial. Rev Chilena Infectol. 2013;30(4):361–373. doi: 10.4067/S0716-10182013000400003 . [DOI] [PubMed] [Google Scholar]
  • 30.Wiwattanarattanabut K, Choonharuangdej S, Srithavaj T. In Vitro Anti-Cariogenic Plaque Effects of Essential Oils Extracted from Culinary Herbs. J Clin Diagn Res. 2017;11(9):DC30–DC35. doi: 10.7860/JCDR/2017/28327.10668 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nozoe T. Uber die farbstoffe im holzteil des ‘Hinoki’-baumes. I. Hinokitin und Hinokitiol. Bull Chem Soc Jpn. 1936;11(3):295–298. [Google Scholar]
  • 32.Yoshida T, Endo K, Ito S, Nozoe T. Chemical constituents in the essential oil of the leaves of Chamaecyparis taiwanensis Masam. Yakugaku Zasshi. 1967;87(4):434–439. doi: 10.1248/yakushi1947.87.4_434 . [DOI] [PubMed] [Google Scholar]
  • 33.Southam CM. Antibiotic activity of extract of western red ceder heartwood. Proc Soc Exp Biol Med. 1946;61:391–396. doi: 10.3181/00379727-61-15330 . [DOI] [PubMed] [Google Scholar]
  • 34.Erdtman H, Gripenberg J. Antibiotic substances from the heart wood of Thuja plicata Don. Nature. 1948;161(4097):719. doi: 10.1038/161719a0 . [DOI] [PubMed] [Google Scholar]
  • 35.Arima Y, Nakai Y, Hayakawa R, Nishino T. Antibacterial effect of beta-thujaplicin on staphylococci isolated from atopic dermatitis: relationship between changes in the number of viable bacterial cells and clinical improvement in an eczematous lesion of atopic dermatitis. J Antimicrob Chemother. 2003;51(1):113–122. doi: 10.1093/jac/dkg037 . [DOI] [PubMed] [Google Scholar]
  • 36.Higashi Y, Sakata M, Fujii Y. High-performance liquid chromatography with dual-wavelength ultraviolet detection for measurement of hinokitiol in personal care products. J Cosmet Sci. 2009;60(5):519–525. PubMed . [PubMed] [Google Scholar]
  • 37.Hiyoshi T, Domon H, Maekawa T, Yonezawa D, Kunitomo E, Tabeta K, et al. Protective effect of hinokitiol against periodontal bone loss in ligature-induced experimental periodontitis in mice. Arch Oral Biol. 2020;112:104679. doi: 10.1016/j.archoralbio.2020.104679 . [DOI] [PubMed] [Google Scholar]
  • 38.Wu EC, Kowalski RP, Romanowski EG, Mah FS, Gordon YJ, Shanks RM. AzaSite® Inhibits Staphylococcus aureus and Coagulase-Negative Staphylococcus Biofilm Formation In Vitro. J Ocul Pharmacol Ther. 2010; 26(6): 557–562. doi: 10.1089/jop.2010.0097 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Mackenzie DW. Serum tube identification of Candida albicans. J Clin Pathol. 1962;15(6):563–565. doi: 10.1136/jcp.15.6.563 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Katakura A. Necessity of providing dental care to medically compromised patients in Japan’s super-aged society and the way forward. Jpn Dent Sci Rev. 2022;58:279–285. doi: 10.1016/j.jdsr.2022.09.002 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Fukui S, Morikawa T, Hirahara M, Terada Y, Shimizu M, Takeuchi K, et al. A mild hand cleanser, alkyl ether sulphate supplemented with alkyl ether carboxylic acid and alkyl glucoside, improves eczema on the hand and prevents the growth of Staphylococcus aureus on the skin surface. Int J Cosmet Sci. 2016;38(6):599–606. doi: 10.1111/ics.12325 . [DOI] [PubMed] [Google Scholar]
  • 42.Okukawa M, Yoshizaki Y, Tanaka M, Yano S, Nonomura Y. Antibacterial activity of the mixed systems containing 1,2-Dodecanediol against Staphylococcus aureus and Staphylococcus epidermidis. J Oleo Sci. 2021;70(6):787–797. doi: 10.5650/jos.ess20362 . [DOI] [PubMed] [Google Scholar]
  • 43.Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis. 2016;74(4):ftw018. doi: 10.1093/femspd/ftw018 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Gulati M, Nobile CJ. Candida albicans biofilms: Development, regulation, and molecular mechanisms. Microbes Infect. 2016;18(5):310–321. doi: 10.1016/j.micinf.2016.01.002 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Jung P, Mischo CE, Gunaratnam G, Spengler C, Becker SL, Hube B, et al. Candida albicans adhesion to central venous catheters: Impact of blood plasma-driven germ tube formation and pathogen-derived adhesins. Virulence. 2020;11(1):1453–1465. doi: 10.1080/21505594.2020.1836902 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Arora DR, Saini S, Aparna, Gupta N. Evaluation of germ tube test in various media. Indian J Pathol Microbiol. 2003;46(1):124–126. PubMed . [PubMed] [Google Scholar]
  • 47.Kim DJ, Lee MW, Choi JS, Lee SG, Park JY, Kim SW. Inhibitory activity of hinokitiol against biofilm formation in fluconazole-resistant Candida species. PLoS One. 2017;12(2):e0171244. doi: 10.1371/journal.pone.0171244 . [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

José António Baptista Machado Soares

31 Mar 2023

PONE-D-23-06120Antibacterial Effect of Oral Care Gel-Containing Hinokitiol and 4-isopropyl-3-methylphenol Against Intraoral Pathogenic MicroorganismsPLOS ONE

Dear Dr. Ohara,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 15 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

José António Baptista Machado Soares, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Additional Editor Comments (if provided):

Dear authors,

The present work is very interesting. However, both reviewers appointed several concerns about the original version of the manuscript. Briefly, both reviewers required English editing and double-checking of results (figures and table) and rewriting of most sections. Please carefully answer all concerns raised by the reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: After the reviewing the submitted manuscript, it must be carefully revised as the following:

1-The title must be more attractive and changed to antimicrobial instead of antibacterial.

2-Introduction must be reconstruct to be more informative and contains tge problem and how the other publicatuons try to solve this problem and how your paper try to solve that.

3-Deep discussion and related and recent studies must br included.

4-The novelty and the future perspective in addition to limitation must be included.

5-Antibiofilm assay must be included in addition to growth kinetics.

6-Reaction mechanism determinant must be performed by FESEM, HRTEM, and membrane leakage assay.

7-English Language editing must be performed by English Native Speaker.

Reviewer #2: The manuscript entitled “Antibacterial Effect of Oral Care Gel-Containing Hinokitiol and 4-isopropyl-3-methylphenol Against Intraoral Pathogenic Microorganisms” is about to provide the evidence for new anti-intraoral pathogenic microorganisms agents.

After first time use, authors can use abbreviation for microorganism’s scientific name. I found Candida albicans several times.

At “Antimicrobial disc diffusion assay”, it is not clear why authors use SCD medium? Why there is no reference?

At the crystal violet assays, it is not clear how to induce the biofilm formation, so authors need to explain more clearly.

At the “Germ tube test”, it is not clear the media is appropriate to induce the germ tube. Please check again.

At line 166, OD may not correct in there. So, check and change.

Authors frequently use bacteria even though the assay include fungi. So, authors need to change that.

At results, authors need to explain the results with the number to make easy to understand.

At discussion, Turbidity is not directly indicative for the level of proliferation. So, authors need to change that.

At discussion, discussion is written usually for explain the results, so if authors add more possible mechanism of HO, that should be a better discussion.

If the HO is a gel-type, how authors weighing the HO? because weight of HO just includes hinokitiol and IPMP, or include hinokitiol and IPMP with some others?

Why authors mixed the hinokitiol and IPMP and what is the ratio?

At figure 1, the figure captured were compared for each bacterium correctly? I think authors need to double check that.

At figure 4, authors need to provide that results statistically and those are hyphae or pseudohyphae? I suggested that authors need to explain about that.

Finally, I could not find table.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. Gharieb S. El-Sayyad

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Sep 1;18(9):e0283295. doi: 10.1371/journal.pone.0283295.r002

Author response to Decision Letter 0


3 Jul 2023

Response to reviewers and editor comments

We are grateful to the reviewers and editor for their helpful comments that have contributed to the improvement of our research paper. The manuscript has benefited from these insightful suggestions. We have provided the responses to the comments below:

Reviewer #1: After the reviewing the submitted manuscript, it must be carefully revised as the following:

1-The title must be more attractive and changed to antimicrobial instead of antibacterial.

→Thank you for pointing it out. The title has been changed according to your suggestion.

2-Introduction must be reconstructed to be more informative and contains the problem and how the other publications try to solve this problem and how your paper try to solve that.

→Thank you for your advice. In lines 57–68 and 93–101 of the introduction, we have included the current problem(s) and the solutions from previous studies and our attempts.

3-Deep discussion and related and recent studies must include.

→We have cited a recent research paper in lines 93–101 of the introduction. Moreover, we have included recent studies in the discussion in lines 218–230, 249–251, and 253–270 of the discussion.

4-The novelty and the future perspective in addition to limitation must be included.

→Thank you for your comment. We have revised the discussion and added the novelty and limitations of the research in lines 271–287 and 292–298, respectively.

5-Antibiofilm assay must be included in addition to growth kinetics.

→Thank you for your suggestion. We have added a description of the anti-biofilm assay in the Material and methods section, lines 154–157. In addition, we have added considerations on anti-biofilm assays in lines 253–263 of the discussion.

6-Reaction mechanism determinant must be performed by FESEM, HRTEM, and membrane leakage assay.

→Thank you for your advice. You are absolutely right; we also think that it is necessary to investigate reaction mechanism using FE-SEM and HR-TEM. However, currently there is a limit to what we can do with our current research equipment and funding; therefore, we were unable to perform these experiments. This is a limitation of our research and has been included as a subject for future study in lines 294–298.

7-English Language editing must be performed by English Native Speaker.

→ English language editing has been performed by an English Native Speaker.

Reviewer #2: The manuscript entitled “Antibacterial Effect of Oral Care Gel-Containing Hinokitiol and 4-isopropyl-3-methylphenol Against Intraoral Pathogenic Microorganisms” is about to provide the evidence for new anti-intraoral pathogenic microorganism agents.

After first time use, authors can use abbreviation for microorganism’s scientific name. I found Candida albicans several times.

→We have corrected the relevant parts in the entire manuscript.

At “Antimicrobial disc diffusion assay”, it is not clear why authors use SCD medium?

Why there is no reference?

→Thank you for your comment. SCD medium is commonly used as a medium for Candida species; therefore, to unify the experimental conditions in this study, SCD medium was used. Sufficient growth was observed in SCD medium for all fungi and bacterium used herein.

At the crystal violet assays, it is not clear how to induce the biofilm formation, so authors need to explain more clearly.

→We have included information on biofilm formation in the Material and methods in lines 154–158.

At the “Germ tube test”, it is not clear the media is appropriate to induce the germ tube. Please check again.

→Thank you for your advice. We have checked our data again, and since significant formation of germ tubes was observed in C. albicans cultured in SCD broth, we believe that the medium used in this study is suitable for formation of germ tubes.

At line 166, OD may not correct in there. So, check and change.

→We have double-checked the OD values and added/corrected these in lines 202–204.

Authors frequently use bacteria even though the assay include fungi. So, authors need to change that.

→Thank you for your comment. We have carefully corrected this in the entire manuscript by distinguishing between fungi and bacterium.

At results, authors need to explain the results with the number to make easy to understand.

→We added a description of the results numerically in lines 181–187 and 214–216.

At discussion, Turbidity is not directly indicative for the level of proliferation. So, authors need to change that.

→Thank you for your comment. We have presented turbidity to simply refer to "possibility of proliferation" in lines 148–151.

At discussion, discussion is written usually for explain the results, so if authors add more possible mechanism of HO, that should be a better discussion.

→Thank you for your advice. We mentioned the possible mechanism of HO in the Discussion in lines 288–294.

If the HO is a gel-type, how authors weighing the HO? because weight of HO just includes hinokitiol and IPMP, or include hinokitiol and IPMP with some others?

→Thank you for your question. HO in the tube was placed directly into a sterile 15 mL or 50 mL centrifuge tube and weighed using an electronic balance. In addition to hinokitiol and IPMP, HO contains an anti-inflammatory ingredient (glycyrrhizinate dipotassium), a solvent (purified water), a humectant system (concentrated glycerin, propylene glycol, hydrolyzed collagen, sodium hyaluronate), a solubilizer (polyoxyethylene hydrogenated castor oil), a viscosity adjuster (carboxyvinyl polymer, sodium polyacrylate), a pH adjuster (potassium hydroxide), a preservative (sodium benzoate), a flavoring agent (flavor), and a stabilizer (ethylenediaminetetraacetic acid disodium).

Why authors mixed the hinokitiol and IPMP and what is the ratio?

→Hinola® (HO) is an oral care gel developed by Otsuka Pharmaceutical Co., Ltd. Hinokitiol, which is extracted from Cupressaceae plants. It has long been used in daily life for its insect repellent, deodorant, and antibacterial effects. IPMP has broad-spectrum bactericidal properties and is effective against bacteria or fungi. For example, it is often used in acne care products to suppress acne-causing bacteria, and in antiperspirants to suppress the growth of odor-causing bacteria. These two ingredients are still used in various common daily products today, and have been applied in the dental field, leading to the development and commercialization of Hinola® (0.1% hinokitiol and 0.02% IPMP).

At figure 1, the figure captured were compared for each bacterium correctly? I think authors need to double check that.

→Thank you for pointing this out. The acquisition and measurement of the images in figure 1 were all performed under the same conditions. We also reconfirmed that the images captured were correctly compared for each bacterium.

At figure 4, authors need to provide that results statistically and those are hyphae or pseudohyphae? I suggested that authors need to explain about that.

→Thank you for your suggestion. We compared the number of germ tube-producing cells in 500 cells between the control group and the HO-added group, and performed this in three sections. We next statistically analyzed and graphed the results (Fig. 4B).

Candida albicans cultured in SCD broth formed biofilms (Fig. 3). Since hyphae are necessary for biofilm formation, we believe that the images are hyphae rather than pseudohyphae (Fig. 4A). We mentioned this in lines 271–272 of the Discussion.

Finally, I could not find table.

→Please accept our sincerest apologies. We have uploaded the missing table.

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 1

José António Baptista Machado Soares

31 Jul 2023

PONE-D-23-06120R1Antimicrobial Effect of Oral Care Gel-Containing Hinokitiol and 4-isopropyl-3-methylphenol Against Intraoral Pathogenic MicroorganismsPLOS ONE Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 14 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Dear authors,

I am pleased to say that the reviewers enjoyed the manuscript very much and we are excited about the possibility to publish your work. One reviewer already endorsed the revised manuscript for publication, while another reviewer asked for clarification about Table 1 in lines 192 and 236 and to increase the resolution of all figures. So, I kindly invite the authors to realize these minor rectifications to finally endorse your study.

Thank you and best regards,

António Machado

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: After the complete revision of the submitted manuscript and following the authors response, the manuscript can be accepted for publication.

Reviewer #2: There is a table 1 in line 192 and 236, but I could not find table1.

Authors need to increase the resolution of all figure.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. Dr. Gharieb S. El-Sayyad

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Sep 1;18(9):e0283295. doi: 10.1371/journal.pone.0283295.r004

Author response to Decision Letter 1


8 Aug 2023

Response to Reviewers

We sincerely appreciate to the reviewers for their supports that have contributed to the improvement of our research paper. We have provided the responses to the comments below:

Reviewer #2: There is a table 1 in line 192 and 236, but I could not find table1.

Authors need to increase the resolution of all figure.

→Please accept our sincerest apologies. We have included table 1 as part of our main manuscript after "References". In addition, we have tried to improve the resolution of the all figures as much as possible. We kindly ask for your confirmation.

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 2

José António Baptista Machado Soares

22 Aug 2023

Antimicrobial Effect of Oral Care Gel-Containing Hinokitiol and 4-isopropyl-3-methylphenol Against Intraoral Pathogenic Microorganisms

PONE-D-23-06120R2

Dear Dr. Ohara,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

José António Baptista Machado Soares, PhD

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

José António Baptista Machado Soares

24 Aug 2023

PONE-D-23-06120R2

Antimicrobial Effect of Oral Care Gel Containing Hinokitiol and 4-isopropyl-3-methylphenol Against Intraoral Pathogenic Microorganisms

Dear Dr. Ohara:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. José António Baptista Machado Soares

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES